Kamada (KMDA): Phase II Trial Adds Support For Inhaled AAT Therapy - Jefferies
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Jefferies analyst, Raj Denjoy, reiterated his Buy rating on shares of Kamada Ltd. (NASDAQ: KMDA) after the company reported Phase II US trial results for inhaled AAT. The analyst believes that the trial showed statistically significant increases of both AAT & ANEC levels in the lung compared to the placebo. While the study was not designed to show clinical benefits, it showed that inhaled AAT effectively reaches lung tissue, where AAT deficiency manifests over time as worsening lung function. As such, the trail lends crucial support to a mid-17 EU approval and continuing the US clinical program.
No change to the price target of $7.
Shares of Kamada Ltd. closed at $4.89 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Slashes PT, Estimates on Chipotle Mexican Grill (CMG)
- ARIAD Pharma (ARIA): Cutting PT On Iclusig Pricing - Jefferies
- Jefferies Cuts Price Target on ResMed (RMD) to $56 Following 1Q Miss
Create E-mail Alert Related CategoriesAnalyst Comments, FDA
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!